Eckert & Ziegler signed Tb-161 deal: Eckert & Ziegler stock gains 2.92 percent
Published on 10/16/2026 at 10:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCatalyst and valuation
- Eckert & Ziegler signed the Terbium-161 supply agreement on October 13, 2026.
- First-half 2026 revenue reached EUR 149.3 million and adjusted EBIT reached EUR 33.3 million.
- Eckert & Ziegler stock trades at EUR 12.68 at 10:04 a.m. CEST at Lang & Schwarz on October 16, 2026, 2.92 percent above the Xetra close of October 15, 2026.
- NuWays set a EUR 21.50 price target on October 13, 2026.
Eckert & Ziegler (ISIN DE0005659700) was trading at EUR 12.68 at Lang & Schwarz on October 16, 2026, at 10:04 a.m. CEST, 2.92 percent above the Xetra close of October 15, 2026. On October 13, 2026, the company signed a Terbium-161 supply agreement with TerThera for its Brazilian business, as Les Echos reported.
Three dated steps shape the story
On August 13, 2026, Eckert & Ziegler reported first-half revenue of EUR 149.3 million and adjusted EBIT of EUR 33.3 million, according to Quartr. On October 13, 2026, NuWays rated the stock Buy and set a EUR 21.50 target, according to EQS News. Later on October 13, 2026, the Terbium-161 agreement was announced for Brazil, linking the company to a new radiopharmaceutical supply chain.
What supports the valuation?
The analyst target stands 69.56 percent above the Lang & Schwarz price, calculated from EUR 21.50 and EUR 12.68. NuWays based its view on independent isotope supply and specialist manufacturing, while the company described the Brazil agreement as a way to expand access to next-generation radioligand therapies. The operating comparison is mixed: first-half revenue was EUR 149.3 million, while adjusted EBIT was EUR 33.3 million, according to Quartr.
Dates investors can verify
The next two scheduled company dates are the quarterly report on November 12, 2026, and the annual financial report on March 24, 2027, according to MarketScreener. The November report will provide the next quantified test of the 2026 outlook.
Stock price and company profile
Eckert & Ziegler operates in healthcare and medical specialties through its Medical and Isotope Products segments. Its 2025 revenue was EUR 312.0 million, while adjusted EBIT was EUR 77.7 million, according to the company investor page. The stock is listed on Xetra and belongs to the TecDAX.
The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.
Eckert & Ziegler stock key data
- Company: Eckert & Ziegler SE
- ISIN: DE0005659700
- WKN: 565970
- Ticker: EUZ
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 16, 2026, 10:04 a.m. CEST): EUR 12.68
- Change versus Xetra close: plus 2.92 percent
- Xetra close (October 15, 2026): EUR 12.32
- Market capitalization: EUR 792.8 million (as of October 16, 2026)
- 52-week range: EUR 11.91-17.73 (as of October 16, 2026)
- Sector / Industry: Healthcare / Medical - Specialties
- Index membership: TecDAX
- Next earnings date: November 12, 2026
Market context: Market report DAX.
